ICYMI: UCB announced positive top-line results from Phase 3 BE COMPLETE study, bimekizumab, in active psoriatic arthritis, who failed TNFi. Bimekizumab pts showed a 50% ACR50 at week 16, as well as signif improvements in PASI90, MDA, PGA https://t.co/HhVdIhqHoL